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Abstract 
This study aimed to evaluate the absorbed doses received by the organs at risk (OARs) following prostate 
treatment with permanent Iodine-125 (125I) brachytherapy seeds. In order to simulate an enlarged 
abnormal prostate due to malignancy, the MIRD5 adult male anthropomorphic phantom (readily available 
in the Geant4 Monte Carlo package) was modified by increasing the prostate volume to 35 cm3. The 
permanent seeds were constructed with an outer cylindrical dimension of 4.5 mm (length) x 0.8 mm 
(diameter). The effects of various activity per seed (0.5, 0.6 and 0.8 mCi), number of seeds (62, 78, 94 and 
110 seeds) and radionuclides, i.e. Palladium-103 (103Pd), 125I and Cesium-131 (131Cs), towards the 
absorbed dose to the OARs (i.e. rectum, urinary bladder and both testicles) were investigated. In this 
study, prostate dose of up to 237 Gy was simulated, which resulted in 11 Gy dose to rectum, 7 Gy to 
urinary bladder and 4 Gy to each testicle. The doses were considered as reasonable, given the low dose 
rate nature of the treatment, allowing tissue repair for the OARs. Optimal seeds arrangement was found to 
consist of 78 or fewer seeds, as it resulted in the lowest dose to the OARs. For similar prostate dose, 
103Pd resulted in the lowest dose to the OARs, followed by 125I and 131Cs. Permanent seed 
brachytherapy allows high dose to be delivered to the prostate, while ensuring minimal dose to the OARs. 
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Abstract. This study aimed to evaluate the absorbed doses received by the organs at risk 
(OARs) following prostate treatment with permanent Iodine-125 (125I) brachytherapy seeds. In 
order to simulate an enlarged abnormal prostate due to malignancy, the MIRD5 adult male 
anthropomorphic phantom (readily available in the Geant4 Monte Carlo package) was 
modified by increasing the prostate volume to 35 cm3. The permanent seeds were constructed 
with an outer cylindrical dimension of 4.5 mm (length) × 0.8 mm (diameter). The effects of 
various activity per seed (0.5, 0.6 and 0.8 mCi), number of seeds (62, 78, 94 and 110 seeds) 
and radionuclides, i.e. Palladium-103 (103Pd), 125I and Cesium-131 (131Cs), towards the 
absorbed dose to the OARs (i.e. rectum, urinary bladder and both testicles) were investigated. 
In this study, prostate dose of up to 237 Gy was simulated, which resulted in 11 Gy dose to 
rectum, 7 Gy to urinary bladder and 4 Gy to each testicle. The doses were considered as 
reasonable, given the low dose rate nature of the treatment, allowing tissue repair for the 
OARs. Optimal seeds arrangement was found to consist of 78 or fewer seeds, as it resulted in 
the lowest dose to the OARs. For similar prostate dose, 103Pd resulted in the lowest dose to the 
OARs, followed by 125I and 131Cs. Permanent seed brachytherapy allows high dose to be 
delivered to the prostate, while ensuring minimal dose to the OARs. 
1.  Introduction 
Permanent prostate brachytherapy is a renowned and common treatment option for the management of 
early-stage prostate cancer. Commonly used radionuclides include Iodine-125 (125I) (Ē = 28 keV, half-
life, t1/2 = 60.0 d), Palladium-103 (103Pd) (Ē = 21 keV, t1/2 = 17.0 d) and Cesium-131 (131Cs) (Ē = 29 
keV, t1/2 = 9.7 d). Instead of other alternatives, such as external beam radiotherapy (EBRT) or radical 
prostatectomy, this treatment is often preferred due to perceived advantages over urinary, bowel and 
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sexual functions [1]. Although serious morbidity is rare, proctitis has been reported in 1–9 % of the 
patients [2], while urethral strictures, incontinence and prolonged irritative symptoms may also occur.  
The estimations of dose to the organs at risk (OARs), i.e. urinary bladder, rectum and both testicles, 
are therefore crucial in preparation for any possible complications. However, direct dose 
measurements may not be possible, without involving invasive procedure. Furthermore, placing 
dosimeters onto the organs will be challenging as not all dosimeters are size-appropriate and suitable 
to be placed onto wet surfaces, as it can affect the device performance. Handheld dosimeter may be 
useful to estimate the dose at the patient’s skin surface, while dose estimation for other OARs will not 
be feasible.   
Monte Carlo (MC) radiation simulation has been increasingly used for dosimetric assessment of 
internal organs following radiation treatment [3]. Geant4 is one of the newest MC code packages, 
which provides accurate probability estimation of radiation events, with flexible geometric 
manipulation for various purposes, especially in medical physics. In this study, the effects of different 
activity per seed, number of seeds, and radionuclide source used, towards the dose received by the 
OARs were evaluated using the Geant4 package. 
2.  Methodology 
2.1.  The MIRD5 phantom 
The study was performed using Geant4.10.0.p03 [4, 5] advanced example human_phantom. The 70 kg 
phantom was adopted from MIRD Pamphlet 5, with a height of 174 cm [6]. Male phantom was 
selected, which was equipped with male genitalia and testicles, however, without the presence of a 
prostate. Thus, an oval shaped prostate was created, and positioned inferior to the urinary bladder 
(Figure 1a). The prostate volume was set to 35 cm3, which represents an enlarged prostate due to 
malignancy [7].  
In the example, the rectum was initially combined with the sigmoid and ascending colons as the 
‘lower large intestine (LLI)’. However, for this study, the rectum was separated from the LLI, by 
creating a separate cylinder with a volume of 70 cm3 [8]. The rectum was positioned posterior to the 
prostate (Figure 1b).  
(a)                                   (b)  
Figure 1. The (a) lateral and (b) frontal views of the MIRD5 phantom’s pelvic region showing the urinary 
bladder, prostate, testicles and rectum. 
2.2.  Designs of permanent seeds  
2.2.1.  125I seed. The seed was constructed based on ADVANTAGETM 125I (IAI-125A, IsoAid L.L.C., 
Port Richey, FL), with 125I as the radioactive source. The seed has an outer dimension of 0.8 mm 
(diameter, d) × 4.5 mm (length, l) [9, 10], as shown in Figure 2. The seed contains a 3 mm silver rod 
(10.5 g.cm-3) with d of 0.5 mm, fully coated with a 1 μm active layer (AgI containing the 125I). The 

















           
Figure 2. The ADVANTAGETM 125I seed as constructed using the Geant4 code. 
2.2.2.  103Pd seed. The seed was constructed based on TheraSeed® (200, Theragenics Co., Buford, 
GA), with 103Pd as the radioactive source. The seed (Figure 3) has similar outer dimension as the 125I 
seed [11]. It consists of two cylindrical graphite pellets (2.27 g.cm-3), coated with 103Pd and separated 
by a cylindrical lead marker (11.34 g.cm-3). Each graphite pellet has a dimension of 0.56 mm (d) × 
0.89 mm (l), while the lead marker is 0.51 mm (d) × 1.09 mm (l). The 103Pd coating is 2.2 μm thick, 
while the thickness of titanium casing is 0.056 mm. The active length is 4.23 mm (two graphite pellets 
and lead marker), calculated using the TG-43 effective line source length approximation [9]. 
              
Figure 3. The TheraSeed® 103Pd seed as constructed using the Geant4 code. 
2.2.3.  131Cs seed. The seed was constructed based on Proxcelan® (CS-1 Rev2, IsoRay Medical Inc., 
Richland, WA), with 131Cs as the radioactive source. The outer dimension of the seed is also similar as 
the 103Pd and 125I seeds [12]. The seed (Figure 4) consists of a 0.25 mm (d) × 4.0 mm (l) gold marker 
(19.3 g.cm-3), which is housed in a 0.62 mm (outer d) (0.4 mm inner d) × 4.0 mm (l) Pyrex/ceramic 
tube (2.4 g.cm-3). The inner surface of the tube is coated with 0.05 mm layer of 131Cs. The housing 
containing the marker is placed in a titanium capsule with 0.1 mm thickness. The void within the 
capsule is filled with argon gas. The corresponding active length is 4.0 mm [9]. 
 
Figure 4. The Proxcelan® 131Cs seed as constructed using the Geant4 code. 
2.3.  Effects of different treatment parameters on the absorbed dose. 
The Low Energy Electromagnetic Package [13], based on the Livermore Evaluated Data Libraries, 
was adopted to model the electromagnetic interactions of photons and electrons. The threshold of 
production of secondary particles was fixed to 1 mm. The Geant4 Radioactive Decay component was 
used to model the decay of the radionuclides.  
The seeds were uniformly arranged and placed inside the prostate as shown in Figure 5c. Uniform 
loading allows all the seeds to be arranged between constant distances, for each x, y and z-axes. This 
resulted in the placement of 94 seeds within the prostate, which was used as the default arrangement 
setup for this study.  
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For every setup, 107 disintegrations were generated and repeated three times, to obtain a standard 
deviation of less than 1 %. The mean energy (MeV) deposited to each OARs was normalized to the 
energy deposited to the prostate. These normalized values were used to obtain the absorbed dose to all 
the OARs, by multiplying the values with the dose prescribed to the prostate, i.e. 145 Gy. 
2.3.1.  Different activity per seed. For this purpose, only the 125I seed was used, with no specific 
prescribed dose. Using the default setup, the activity for each seed was set to 0.49 mCi. The common 
activity per seed used in a permanent 125I prostate implant is in the range of 0.3 to 0.8 mCi [14]. The 
simulation was later repeated by changing the activity per seed to 0.6 and 0.8 mCi. The seeds were 
allowed for full decay and the resulting absorbed dose to the prostate and OARs were recorded. 
2.3.2.  Different number of seeds. For this purpose, again only the 125I seed was used. Different number 
of seeds, i.e. 62, 78, 94 and 110, [15] arranged in the prostate were simulated. The prescribed dose to 
the prostate was maintained to 145 Gy, and the absorbed dose received by the OARs were compared 
between these arrangements. Since the consensus on the optimal seed distribution does not exist [14], 
the classic approach, which is the uniform loading was used to space the seeds with uniform distances. 
The placement of 62, 78, 94 and 110 seeds are shown in Figure 5a, b, c and d. 
(a) (b) (c) (d)  
Figure 5. The placements of (a) 62, (b) 78, (c) 94, and (d) 110 125I seeds within the prostate volume (seen in 
wireframe mode). 
2.3.3.  Different radionuclides. By using the 94 seed arrangement, the simulation was later repeated 
using the 103Pd and 131Cs seeds. The prescribed dose to the prostate was set to 145 Gy, and the 
absorbed dose received by the OARs were compared between these radionuclides. 
3.  Results & Discussions 
3.1.  Different activity per seed 
For 94 seeds configuration, the activity per seed of 0.49 mCi resulted in 145 Gy to the prostate, which 
is the recommended prescribed dose for permanent brachytherapy using the 125I seed. The activity per 
seed of 0.6 and 0.8 mCi resulted in the absorbed dose to prostate of 177 and 236 Gy, respectively. The 
absorbed dose to the OARs for different 125I activity per seed used are shown in Figure 6.  
The rectum was observed to receive the highest dose, followed by urinary bladder and the testicles 
(up to 11, 7 and 4 Gy, respectively, when the 0.8 mCi per seed was used). In general, the dose for each 
organ increased as the activity per seed increased. Although the maximum activity per seed was used, 
the dose to the OARs did not exceed the dose limits for permanent prostate implant, i.e. 90 Gy for 
rectum [14], 20 Gy for testicles [16] and 70 Gy for urinary bladder [17]. 
3.2.  Different number of seeds 
The number of seeds used were 62, 78, 94 and 110, where the activity per seed was adjusted so the 
dose prescribed to the prostate was fixed to 145 Gy. The absorbed dose to the OARs for different 
number of seeds are shown in Figure 7. The rectum was observed to receive the highest dose, followed 
by urinary bladder and the testicles, for all the number of seeds used. The absorbed dose to OARs for 
78 seeds configuration was found to be the lowest, followed by 62, 94, and 110 seeds.  
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The absorbed dose to OARs for 78 seeds were found to be lower than the 62 seeds configuration 
due to its lower activity per seed. However, as the number of seed increases beyond 78, the seeds need 
to be placed closer to the prostate edge, hence resulted in a higher dose to OARs, although the activity 
per seed is lower as the number of seeds increased. 
3.3.  Different radionuclides 
103Pd resulted in the lowest absorbed dose to OARs, followed by 125I and 131Cs (Figure 8), due to 
limited penetration of the emitted radiation energies, hence allowing high dose to be prescribed to the 
prostate, while sparing the surrounding healthy tissues [18].  
On the other hand, 131Cs emits slightly higher energy compared to the other sources, hence, the 
radiation can escape from the source organ and deposits energy to the surrounding organs. However, 
131Cs provides a higher dose rate, which can be beneficial in terms of the duration of treatment. The 
relatively shorter t1/2 of 131Cs (only 7.9 d) allows shorter radiation exposure for the patient’s family and 
the surrounding environment [18]. 
       
                         
4.  Conclusion 
The maximum prostate dose of up to 237 Gy was simulated, which resulted in 11 Gy dose to rectum, 7 
Gy to urinary bladder and 4 Gy to each testicle. These doses were considered as reasonable, given the 
low dose rate nature of the treatment, allowing tissue repair for the OARs. Optimal seeds arrangement 
was found to consist of 78 or fewer seeds, as it resulted in the lowest absorbed dose to the OARs. For 
similar prostate dose, 103Pd resulted in the lowest absorbed dose to the OARs, followed by 125I and 
131Cs. Even though 131Cs resulted in the highest dose to the OARs, the dose to the prostate can be 
delivered faster than the other isotopes, due to its shorter t1/2. 
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